In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

被引:171
作者
Nishimura, Ryosei [1 ]
Baker, Jeanette [1 ]
Beilhack, Andreas [1 ,2 ]
Zeiser, Robert [1 ]
Olson, Janelle A. [1 ]
Sega, Emanuela I. [1 ]
Karimi, Mobin [1 ]
Negrin, Robert S. [1 ]
机构
[1] Stanford Univ, Div Blood & Marrow Transplantat, Dept Med, Stanford, CA 94305 USA
[2] Univ Wurzburg, Dept Med 2, Wurzburg, Germany
基金
美国国家卫生研究院;
关键词
D O I
10.1182/blood-2007-06-092817
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokine-induced killer (CIK) cells are ex vivo-expanded T lymphocytes expressing both natural killer (NK)- and T-cell markers. CIK cells are cytotoxic against autologous and allogeneic tumors. We previously showed that adoptive transfer of allogeneic CIK cells in a murine model caused minimal graft-versus-host disease (GVHD). However, the precise mechanism of reduced GVHD is not fully understood. Therefore, we evaluated the trafficking and survival of luciferase-expressing CIK cells in an allogeneic bone marrow transplant model. The initial trafficking patterns of CIK cells were similar to conventional T cells that induced GVHD; however, CIK cells infiltrated GVHD target tissues much less and transiently. CIK cells accumulated and persisted in tumor sites, resulting in tumor eradication. We evaluated different properties of CIK cells compared with conventional T cells, demonstrating a slower division rate of CIK cells, higher susceptibility to apoptosis, persistent increased expression of interferon gamma (IFN-gamma), and reduced acquisition of homing molecules required for entry of cells into inflamed GVHD target organs that lack expression of NKG2D ligands recognized by CIK cells. Due to these properties, allogeneic CIK cells had reduced expansion and caused less tissue damage. We conclude that CIK cells have the potential to separate graft-versus-tumor effects from GVHD.
引用
收藏
页码:2563 / 2574
页数:12
相关论文
共 37 条
[1]   Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation [J].
Alvarnas, JC ;
Linn, YC ;
Hope, EG ;
Negrin, RS .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (04) :216-222
[2]   Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation [J].
Asai, O ;
Longo, DL ;
Tian, ZG ;
Hornung, RL ;
Taub, DD ;
Ruscetti, FW ;
Murphy, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (09) :1835-1842
[3]   Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production [J].
Baker, J ;
Verneris, MR ;
Ito, M ;
Shizuru, JA ;
Negrin, RS .
BLOOD, 2001, 97 (10) :2923-2931
[4]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[5]   In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets [J].
Beilhack, A ;
Schulz, S ;
Baker, J ;
Beilhack, GF ;
Wieland, CB ;
Herman, EI ;
Baker, EM ;
Cao, YA ;
Contag, CH ;
Negrin, RS .
BLOOD, 2005, 106 (03) :1113-1122
[6]  
Blazar BR, 1999, J IMMUNOL, V162, P6368
[7]   Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism [J].
Blazar, BR ;
Carreno, BM ;
Panoskaltsis-Mortari, A ;
Carter, L ;
Iwai, Y ;
Yagita, H ;
Nishimura, H ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1272-1277
[8]   Shifting foci of hematopoiesis during reconstitution from single stem cells [J].
Cao, YA ;
Wagers, AJ ;
Beilhack, A ;
Dusich, J ;
Bachmann, MH ;
Negrin, RS ;
Weissman, IL ;
Contag, CH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (01) :221-226
[9]   Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study [J].
Chan, JK ;
Hamilton, CA ;
Cheung, MK ;
Karimi, M ;
Baker, J ;
Gall, JM ;
Schulz, S ;
Thorne, SH ;
Teng, NN ;
Contag, CH ;
Lum, LG ;
Negrin, RS .
CLINICAL CANCER RESEARCH, 2006, 12 (06) :1859-1867
[10]   The role of the NKG2D receptor for tumor immunity [J].
Coudert, Jerome D. ;
Held, Werner .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (05) :333-343